CLS07
07 Jun 2021
Trial Summary
The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a potential new way to help diagnose NETs.
Acronym:
CLS07
ACTRN/NCT /ethics:
NCT04438304
Scientific title:
Positron Emission Tomography Imaging of Participants with Known or Suspected Gastroenteropancreatic Neuroendocrine Tumours Using 64Cu-SARTATE: A Multi-Centre, Single Arm, Non-Randomised, Blinded-Review, Phase II study
Sponsor / Cooperative group:
Clarity Pharmaceuticals Ltd
Trial & Patient Characteristics
| Cancer Type | Neuroendocrine |
|---|---|
| Trial Type | Early detection, diagnosis, prognosis |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | All stages |
| Anticipated Start Date | 2021-03-02 |
| Anticipated End Date | 2022-01-08 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Dr Nimit Singhal |
| Recruitment Status | Recruiting |